TipRanks
Vertex Pharmaceuticals (IT:1VRTX)
:1VRTX
Italy Market
1VRTX
Vertex Pharmaceuticals
RESEARCH TOOLSreports

Vertex Pharmaceuticals (1VRTX) Stock News & Sentiment

4 Followers
Goldman Sachs Reiterates Buy on Vertex as Inaxaplin Data De-Risk Outlook; $653 Price Target Reaffirmed
Premium
Ratings
Goldman Sachs Reiterates Buy on Vertex as Inaxaplin Data De-Risk Outlook; $653 Price Target Reaffirmed
3d ago
VRTX
Vertex Top Pick Affirmed as Inaxaplin Progress Supports Pipeline Upside; $672 Price Target Reiterated
Premium
Ratings
Vertex Top Pick Affirmed as Inaxaplin Progress Supports Pipeline Upside; $672 Price Target Reiterated
3d ago
VRTX
Aclaris, EyePoint, Vertex, GitLab, NioCorp Trending With Analysts
Premium
Weekend Updates
Aclaris, EyePoint, Vertex, GitLab, NioCorp Trending With Analysts
21d ago
NB
ACRS
Vertex Tests VX-407’s Impact on Birth Control: What It Means for VRTX Investors
Premium
Company Announcements
Vertex Tests VX-407’s Impact on Birth Control: What It Means for VRTX Investors
29d ago
VRTX
Vertex Advances Kidney Disease Pipeline With Completed Inaxaplin Phase 2b Trial
Premium
Company Announcements
Vertex Advances Kidney Disease Pipeline With Completed Inaxaplin Phase 2b Trial
1M ago
VRTX
Vertex: Competitive Threat Eases, Pipeline Strength Supports Unchanged $600 Price Target and Buy Rating
Premium
Ratings
Vertex: Competitive Threat Eases, Pipeline Strength Supports Unchanged $600 Price Target and Buy Rating
2M ago
VRTX
Vertex Stock (VRTX) Soars 7% as Rival Sionna (SION) Crashes 92% on Failed Drug Trial
Premium
Market News
Vertex Stock (VRTX) Soars 7% as Rival Sionna (SION) Crashes 92% on Failed Drug Trial
2M ago
SION
VRTX
More IT:1VRTX News >

1VRTX News on the Web

Scotiabank Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
TipRanks News
Bullish
Analysts Conflicted on These Healthcare Names: Pfizer (PFE), Celldex (CLDX) and Vertex Pharmaceuticals (VRTX)
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV)
TipRanks News
Neutral
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026
The Motley Fool
Neutral
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
Zacks
Neutral
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?
The Motley Fool
Neutral
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ascendis Pharma (ASND) and Charles River Labs (CRL)
TipRanks News
Bullish
Vertex Pharmaceuticals Incorporated at Morgan Stanley Global Healthcare Conference Transcript
GuruFocus News
Neutral

News Score - Last 7 Days

Very Positive
IT:1VRTX
Sector Average
Media Buzz
This Week26 articles
Weekly Average9 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is IT:1VRTX’s Media Buzz Sentiment?
26 articles about IT:1VRTX were published this week. In an average week, 9 articles are published.
    What is IT:1VRTX’s weekly average amount of articles?
    In an average week, 9 articles about IT:1VRTX are published.
      What is IT:1VRTX’s News Sentiment?
      100% of articles about IT:1VRTX were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        ENTXEntera Bio
        VEEVVeeva Systems
        HELPHelus Pharma
        LGNDLigand Pharma
        ANABAnaptysBio
        Showing the stocks with the most bullish news sentiment over the past week